21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 02.07.2026 Expectation: 500 pips
Buying Brent crude with $102 in view
Today at 11:48 AM 24
Period: 09.06.2026 Expectation: 4000 pips
Go long on Tesla shares with $455 in sight as bulls take back control
Today at 11:12 AM 24
Period: 09.06.2026 Expectation: 450 pips
Selling AUDUSD down to 0.71150 amid weak Australian data and strong American dollar
Today at 07:29 AM 22
Period: 02.07.2026 Expectation: 5830 pips
Selling Bitcoin down to $65,000
Today at 07:03 AM 28
Gold sell
Period: 07.06.2026 Expectation: 1150 pips
Strengthening dollar puts gold under pressure
Yesterday at 10:05 AM 92
Period: 15.06.2026 Expectation: 200 pips
Buying SPX with 7,800 in sight
Yesterday at 09:03 AM 26
Go to forecasts